References
- Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, . Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313:1485–92.
- Goto S, Noguchi A, Jinguji H, Takahara M. The therapeutic potential of immuno-cell therapy of cancer in combination with aminobisphosphonates. Anticancer Res. 2006;26:3989–95.
- Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, . A combination therapy of gemcitabine with immunotherapy for patients with inoperable locally advanced pancreatic cancer. Pancreas. 2009;38:69–74.
- Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet. 2000;356:802–7.
- Ferrarini M, Ferrero E, Dagna L. Human gammadelta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol. 2002;23:14–8.
- Sicard H, Ingoure S, Luciani B, Serraz C, Fournié JJ, Bonneville M, . In vivo immunomanipulation of V gamma 9 V delta 2 T cells with a synthetic phosphoantigen in a preclinical nonhuman primate model. J Immunol. 2005;175: 5471–80.
- Kunzmann V, Bauer E, Feurle J, Weißinger F, Tony HP, Wilhelm M. Stimulation of gamma delta T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood. 2000;96:384–92.
- Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, . Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood. 2003;102: 200–6.
- Abe Y, Muto M, Nieda M, Nakagawa Y, Nicol A, Kaneko T, . Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol. 2009;37: 956–68.
- Kobayashi H, Tanaka Y, Yagi J, Osaka Y, Nakazawa H, Uchiyama T, . Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. Cancer Immunol Immunother. 2007;56:469–76.
- Kondo M, Sakuta K, Noguchi A, Ariyoshi N, Sato K, Sato S, . Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy. 2008;10:842–56.
- Goto S, Sato M, Kaneko R, Itoh M, Sato S, Takeuchi S. Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunologic dysfunction in advanced cancer patients. Cancer Immunol Immunother. 1999;48:435–42.
- Caccamo N, Meraviglia S, Ferlazzo V, Angelini D, Borsellino G, Poccia F . Differential requirements for antigen or homeostatic cytokines for proliferation and differentiation of human Vgamma9Vdelta2 naive, memory and effector T cell subsets. Eur J Immunol. 2005;35:1764–72.